Vigmed receives CE-mark approval and first orders for their new SWiTCH product.

Vigmed announced today that they have received the CE-mark approval for
commercial sales of their new product Vigmed® SWiTCH and that several
distributors already have placed initial orders for the product
“I am very pleased to announce that Vigmed has been granted CE-approval for
SWiTCH by the Notified Body Presafe – in time for our prelaunch campaign, says
Vigmed Director of Quality Assurance and Regulatory Affairs, Ola Lindau.

“The launch of SWiTCH is a major milestone for Vigmed, as it offers our
distributors a premium priced product range to complement their existing Vigmed
portfolio, this enabling them to increase their focus and time offered to sales
of Vigmed products”, says CEO Finn Ketler. He continues, “The interest in SWiTCH
has been significant as it offers the first safety product of its kind, this is
reflected in the fact that the first orders have already been received”.

SWiTCH is a needle protected peripheral arterial catheter, allowing users to
control potential blood loss both during insertion as well as during subsequent
treatment of the patient. It fulfils the requirement in the EU safety directive
and adds a unique product to Vigmed’s range of patented safety devices developed
in their continuous efforts to eliminate the risks and hazards of needlestick
injuries.

"This specially developed product has been eagerly awaited by Vigmed's partners
and end-users, given it broadens the safety offering to the Critical Care and
Anesthesia markets”, says Vigmed Director of Sales and Marketing, Mike Dooley.
“The commercialization effort started four months ago, and having received the
CE-mark, the pre-launch campaign is now being rolled out.”
För vidare information kontakta:

CEO, Finn Ketler, +46 42 600 5311 or Director of Quality Assurance & Regulatory
Affairs, Ola Lindau, +46 42 600 5315
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market patented, needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed’s
share is traded on NASDAQ OMX First North Premier in Stockholm (ticker VIG) and
has approximately 5 600 shareholders. Remium Nordic AB is the Company’s
Certified Advisor.

Additional information about the company can be found on Vigmed’s
website: www.vigmed.com/investor